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ABSTRACT
Purpose: To evaluate the effect of intravitreal bevacizu-
mab (Avastin) injections on visual acuity (VA) and foveal
retinal thickness in patients with macular oedema
secondary to branch retinal vein occlusion.
Methods: A prospective, non-comparative, consecutive,
interventional case series of 34 patients. Patients received
repeated intravitreal injections of 1.25 mg bevacizumab.
Main outcome measures were VA (Snellen charts and
ETDRS) and retinal thickness (optical coherence tomo-
graphy measurements) in a follow-up period of 6 months.
Results: Patients presented at a mean age of 69 years
(range 44–86). Mean duration of symptoms was
40 weeks (range 1–300). Mean (SD) VA at baseline was
0.79 (0.39) logMAR, improving to 0.51 (0.34) logMAR at
6 months (p = 0.009). Mean number of letters on the
ETDRS chart at baseline was 45.3 (19.0), improving to
60.6 (19.9) at 6 months (p = 0.003). Mean (SD) retinal
thickness at baseline was 474 (120) mm, declining to 316
(41) mm at 6 months.
Conclusion: Intravitreal injection of 1.25 mg bevacizumb
appears to be an effective treatment option for branch
retinal vein occlusion.
Branch retinal vein occlusion (BRVO) is a common
retinal vascular disorder of the elderly.
Associated risk factors include advanced age
(usually 60–70 years), arterial hypertension,
arteriolosclerosis, diabetes mellitus, hyperlipidae-
mia and smoking.1 Visual acuity is usually affected
only when the area of ischaemia includes the
macula or if secondary oedema and/or bleeding
involve the macula. The only evidence-based
treatment available for macular oedema secondary
to BRVO is retinal grid laser photocoagulation
based on the results of the Branch Vein Occlusion
Study.2 However, visual outcome for laser-treated
patients in this study was a mean gain of 1.33 lines,
suggesting the need for advanced therapeutic
measurements. In addition, one major drawback
of laser photocoagulation is its after-effect of visual
field defects, which my increase over time.
Recent studies have shown vascular endothelial
growth factor (VEGF) to play a crucial role in the
pathogenesis of retinal oedema secondary to vaso-
occlusive disease.3–5 VEGF has been reported to
destabilise endothelial tight junctions and promote
endothelial cell proliferation secondary to ischae-
mia, both conditions found in vaso-occlusive
retinal disease.6 7 Upregulation of VEGF is asso-
ciated with the breakdown of the blood/retina
barrier, with the increased vascular permeability
resulting in retinal oedema, stimulation of
endothelial cell growth, and neovascularisation.8–10
Thus pharmacological inhibition of VEGF appears
to be a promising approach for treatment of
BRVO, in which the breakdown of the blood/
retinal barrier and neovascularisation have impor-
tant roles.
The VEGF inhibitor bevacizumab (Avastin,
rhuMAb-VEGF; Genentech, South San Francisco,
California, USA) is a full-length humanised mono-
clonal antibody approved by the Food and Drug
Administration, which was originally developed
for the treatment of metastatic colorectal cancer. It
has recently emerged as a novel therapeutic
strategy for retinal diseases, especially age-related
macular degeneration, and, in retrospective short-
term studies, has also proven to be effective in
central retinal and branch retinal vein occlusion.5 11
None of the clinical and experimental studies
published so far have found any drug-related toxic
effects on any retinal structures.
This study was conducted to prospectively
evaluate the effect of intravitreal administration
of 1.25 mg bevacizumab on macular oedema and
visual function secondary to BRVO.
METHODS
Study design
This study was designed as a prospective, con-
secutive, non-comparative case series.
Patient eligibility with regard to diagnosis of
macular oedema after BRVO was confirmed from
optical coherence tomography (OCT) images,
fluorescein angiograms and fundus photographs.
Patients who had received previous laser treatment
within the preceding 6 months were excluded.
All patients gave their written informed consent.
They were specifically informed about the off-label
character of the treatment and the potential risk of
retinal detachment and endophthalmitis, as well as
the fact that additional treatment might be
required. The study was performed in accordance
with the Declaration of Helsinki. Only one eye was
selected as the study eye.
In an initial step, patients received an intravitreal
injection of 1.25 mg bevacizumab on day 1 and 4
weeks thereafter. After the second injection, the
decision on further intravitreal administration of
bevacizumab was made on the basis of treatment
success, ineffectiveness or toxicity as determined
by evaluation of visual acuity and OCT findings.
Patients underwent monthly visual acuity testing,
ocular pressure measurement, slit lamp and stereo-
scopic fundus examination, OCT imaging, and
fundus photography.
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Owing to the off-label character of the intravitreal bevacizu-
mab treatment, a strict treatment protocol was developed to
avoid ineffective treatment.
Treatment success
Treatment success after the second intravitreal bevacizumab
injection was determined as follows: (a) best corrected visual
acuity score of the study eye of >79 letters (approximate
Snellen equivalent of >20/30); (b) average retinal thickness in
the OCT central subfield of (225 mm. If treatment was
discontinued because of success, the patient nevertheless
continued to undergo the scheduled monthly assessments.
Treatment was restarted if the average macular thickness of the
study eye increased by >50 mm, as assessed on OCT scans, or
visual acuity decreased by >5 letters and was ,74 letters.
Treatment ineffectiveness (ie, not even borderline improvement)
If two consecutive monthly bevacizumab injections had not
produced at least borderline improvement in the study eye, the
treatment was discontinued. Borderline improvement was
defined as follows: (a) a decrease in mean retinal thickening of
the study eye of at least 50 mm; (b) an increase in best corrected
visual acuity score of at least 5 letters. If the study eye did not
show borderline improvement, further treatment with bevaci-
zumab injections was discontinued at the 2-month follow-up.
Patients who discontinued treatment for this reason were
also enrolled in the scheduled monthly assessments.
Outcome measures
The main outcome measures of the treatment were central
retinal thickness and visual function. Best corrected visual
acuity was tested using Snellen-adjusted charts (Moeller-Wedel
M3000, Wedel, Germany) projected at 5 m distance with
numeric presentation. Letter numbers were then evaluated
using ETDRS charts (Lighthouse International, New York,
USA).12 Additional assessments, consisting of intraocular
pressure measurement, slit lamp examination, bilateral stereo-
scopic fundus biomicroscopy using a 78 diopter lens, retinal
thickness measurement using OCT (Stratus OCT-3000; Carl
Zeiss Meditec, Dublin, California, USA), and fundus photo-
graphs of the posterior pole and the macular area, were
performed before treatment and during the follow-up examina-
tions 14 days, 6 weeks and 3, 4 and 6 months after treatment.
For statistical analysis, Snellen acuity was converted into the
corresponding value in logarithmic minimal angle of resolution
(logMAR).
Injection technique
Topical anaesthesia was achieved before injection using 1%
tetracaine eye drops. Before injection, the eye was scrubbed
with 10% povidone/iodine. Patients then received a unilateral
intravitreal injection of 0.05 ml containing 1.25 mg bevacizu-
mab using a sharp 27-gauge needle at a distance of 3.5–4.0 mm
from the limbus.
Statistical analysis
All data were collected in a MS-Excel 2000 spreadsheet
(Microsoft Corporation, Unterschleissheim, Germany) and
analysed using SPSS V13.0 for Windows (SPSS Inc, Chicago,
Illinois, USA). For statistical analysis, the Wilcoxon test was
applied for comparison of multivariables within one group (eg,
initial visual acuity versus final visual acuity) and the Mann–
Whitney U test was performed for comparison of differences
between subgroups. For all statistical tests, p,0.05 was
considered significant.
RESULTS
Thirty-four patients (21 male) with retinal oedema involving
the centre of the macula secondary to BRVO were evaluated.
Patients presented at a mean age of 69 years (range 44–86).
Mean duration of symptoms from BRVO until study inclusion
was 40 weeks (range 1–300). All 34 patients completed the 6-
month observation period, attending all control visits.
Fourteen (41%) of the 34 eyes had been pretreated. Two eyes
(6%) had received a pars plana vitrectomy with peeling of
epiretinal membranes, one with and one without additional
sheathotomy. Eleven eyes (32%) had received laser photocoa-
gulation for treatment of macular oedema, three of them
combined with intravitreal injection of triamcinolone acetate.
One patient (3%) had received an intravitreal injection of
triamcinolone acetate alone. The remaining 20 (59%) had not
been treated before study inclusion.
The mean number of intravitreal injections performed during
the study period was 2.9. Altogether, 15 (44%) eyes received
two, 10 (29%) eyes three, six (18%) eyes four, two (6%) eyes
five, and one (3%) eye six injections.
Overall mean (SD) visual acuity at baseline was 0.79 (0.39)
logMAR (20/120), improving to 0.51 (0.34) logMAR (20/60) at 6
months (p,0.001) (table 1). To be more precise, whereas 29
(85%) of the 34 eyes included in the study initially had visual
acuity worse than 20/40 and only five eyes with 20/40 or better
(15%), at 6 months, the visual acuity was worse than 20/40 in
only 21 cases (62%) and was 20/40 or better in 13 cases (38%).
At 6 months, the gain in visual acuity was two or more lines in
21 (62%) and four or more lines in 12 (35%) of the 34 cases.
At baseline, the mean number of letters was 45.3 (19.0) and
this improved to 60.6 (19.9) at 6 months (p,0.001). Overall,
mean gain between baseline and 6 months was 15.3 (13.5)
letters (p,0.001).
Retinal thickness measured by OCT was 474 (120) mm at
baseline and declined to 316 (41) mm at 6 months (p,0.001).
Subgroup analysis of pretreated cases versus those not
pretreated revealed some statistically significant differences.
The 14 pretreated eyes showed a mean visual acuity of 0.91
(0.40) logMAR (20/160) at baseline and a mean of 38.0 (17.4)
letters, whereas the 20 eyes that had not been pretreated
showed a mean baseline visual acuity of 0.71 (0.38) logMAR
(20/200) and a mean of 50.4 (18.9) letters (p = 0.120 and 0.047,
respectively). At 6 months, eyes that had not been pretreated
showed a mean visual acuity of 0.37 (0.27) logMAR (20/50) and
a mean of 67.7 (16.5) letters and pretreated eyes achieved a
mean visual acuity score of only 0.70 (0.36) logMAR (20/200)
and a mean of 50.5 (20.6) letters (p = 0.04 and 0.012,
respectively) (figs 1 and 2). In addition, there was a mean letter
Table 1 Visual acuity (logMAR, letters on ETDRS chart and OCT) after
treatment with bevacizumab
Baseline 2 weeks 6 weeks 3 months 6 months
logMAR 0.79 (0.39) 0.64 (0.41)* 0.55 (0.35)* 0.49 (0.39)* 0.51 (0.34)*
ETDRS 45.3 (19.0) 51.4 (20.8)* 58.7 (19.8)* 64.1 (21.4)* 60.6 (19.9)*
OCT 474 (120) 368 (82)* 333 (66)* 331 (58)* 316 (41)*
Values are mean (SD).
*p,0.05 compared with baseline value (Wilcoxon test).
logMAR, logarithm of minimal angle of resolution; OCT, optical coherence tomography.
Clinical science
352 Br J Ophthalmol 2008;92:351–355. doi:10.1136/bjo.2007.123513
 group.bmj.com on April 24, 2013 - Published by bjo.bmj.comDownloaded from 
gain of 17.3 (15.3) for eyes that had not been pretreated
compared with only 12.5 (11.3) in pretreated eyes (p = 0.592).
Although treatment effects in non-pretreated eyes seemed
more pronounced, both pretreated and untreated eyes showed
significant improvement, as assessed by both logMAR visual
acuity (p = 0.012, p = 0.004, respectively) and letter scores
(p,0.001 for both).
Comparison of retinal thickness measured by OCT between
the two groups revealed no significant differences at either
baseline or 6 months (p = 0.478 and 0.071, respectively) (fig 3).
At baseline, pretreated eyes had a mean central retinal thickness
of 492 (179) mm, decreasing to 332 (28) mm after 6 months
(p = 0.004), and the eyes that had not been pretreated had a
baseline retinal thickness of 471 (111) mm, which declined to
304 (46) mm at 6 months (p,0.001).
Further subgroup analysis was performed to evaluate the effect
of the duration of symptoms (decrease in visual acuity secondary
to BRVO) before initiation of treatment with intravitreal
injections of bevacizumab. In 13 (38%) eyes, treatment was
initiated within 90 days of the initial decrease in visual acuity, and
21 (69%) patients were treated more than 90 days after the initial
perception of visual decline. Statistical analysis of these two
subgroups revealed no significant difference in visual acuity or
central retinal thickness (each p.0.366).
In five eyes (15%), minimal recurrent exudation with macula
oedema was found at the 5-month visit. In all these cases, the
macula was considered to be dry at the 4-month control visit
after three intravitreal injections of bevacizumab. At the 5-
month visit, these eyes showed new minor exudation with little
decrease in visual acuity. After fluorescence angiographic
evaluation, additional focal laser photocoagulation was per-
formed. Exudation was successfully eliminated and retinal
thickness was stabilised at the 6-month visit.
Figure 1 Comparison of visual acuity results between pretreated
(n = 14) and non-pretreated (n = 20) cases of branch retinal vein
occlusion.
Figure 2 Comparison of ETDRS letter scores between pretreated
(n = 14) and non-pretreated (n = 20) cases of branch retinal vein
occlusion.
Figure 3 Comparison of central retinal thickness (measured by optical
coherence tomography) between pretreated (n = 14) and non-pretreated
(n = 20) cases of branch retinal vein occlusion.
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No side effects of the intravitreal injection of bevacizumab
were seen.
DISCUSSION
Inhibitory drugs for the VEGF receptor have found their way
into ophthalmology for the treatment of various diseases. The
first to be introduced was bevacizumab (Avastin), a humanised
monoclonal antibody that had previously been used for the
treatment of metastatic colorectal cancer. Although it is an off-
label drug because of its low toxic side effects, its use in
ophthalmology worldwide has shown an unprecedented
increase.13 Previous studies have demonstrated its effectiveness
in reducing macular oedema in eyes with retinal vein occlusions
and age-related macular degeneration.5 14–16
This is the first large prospective clinical trial to demonstrate
the effectiveness of intravitreal bevacizumab in reducing
macular oedema. The OCT findings show a statistically
significant reduction in central retinal thickness at all study
time points. Moreover, mean visual acuity scores show
significant improvement at all follow-up visits compared with
baseline findings: a mean gain of three lines due to a mean
increase of 15.3 letters on the ETDRS chart among all the
patients.
One drawback of this study is the lack of testing of functional
visual acuity, such as reading tests. In patients with focal
macular oedema, reading problems are more pronounced than
basic recognition of distantly presented optotypes. Evaluation
of possible gains in reading performance is planned in a future
study.
Subgroup analysis of early versus delayed treatment with
intravitreal bevacizumab revealed no significant differences in
visual acuity prognosis. This is in contrast with earlier findings
of our group on treatment of macular oedema secondary to
central retinal vein occlusion with intravitreal bevacizumab.16 In
BRVO, unlike central retinal vein occlusion, perfusion of retinal
structures can still be achieved by collaterals to the non-
perfused area. This presumably results in less, or delayed,
chance of irrevocable damage to the macula, with better
prognosis for visual acuity even after delayed treatment of the
oedema.
Although there is some controversy about its effectiveness,
laser photocoagulation has been proposed to be the best
treatment for persistent macular oedema following BRVO.17 18
In our study, five patients showed mild recurrent exuda-
tion after initially successful bevacizumab treatment. In these
patients, complete resorption of macular oedema could be
achieved with additional focal laser photocoagulation. Retinal
thickness and visual acuity were stable for the whole follow-
up period. Two of these cases were pretreated (with pars
plana vitrectomy and peeling of the epiretinal membrane)
and three were not. From these results, one could conclude
that a combined treatment of bevacizumab and focal laser
photocoagulation might be an even more effective approach.
However, considering the non-pretreated cases, only two
(10%) of 20 patients in our trial needed additional laser
treatment. Further studies will be necessary to determine
whether this combined treatment would reduce the number
of bevacizumab injections needed to resolve persistent
oedema or if bevacizumab treatment can effectively reduce
the necessity for grid laser photocoagulation in the long
term.
Subgroup analysis revealed that pretreatment of BRVOs
before bevacizumab injections resulted in a worse prognosis
than when bevacizumab was the initial treatment. Barbazetto
and Schmidt-Erfurth19 have shown that grid laser photocoagula-
tion causes an increase in central scotoma size in patients with
macular oedema after BRVO. Laser treatment led to decreased
mean visual acuity scores in these eyes after 3 months.
Analogously to that study, most pretreated eyes in our study
had laser photocoagulation, which may explain the reduced
visual acuity in this subgroup. In addition, the duration of
symptoms was significantly longer in the pretreated cases than
the non-pretreated cases: 53.7 (49) vs 28.7 (68) weeks
(p = 0.001). The longer duration of macular oedema may also
have contributed to the worse results for visual acuity.
Although this may be true, even these eyes benefited from the
intravitreal bevacizumab injections, on average, gaining 12.5
letters on the ETDRS chart.
In the Branch Vein Occlusion Study, eyes with macular
oedema after BRVO either received grid laser photocoagulation
or remained untreated. Eyes either received grid laser photo-
coagulation or remained untreated. After 3 years, 63% of eyes in
the laser-treated group had gained two or more lines, whereas
only 36% of untreated eyes reached that level.2 Bevacizumab
treatment of BRVOs in the present study produced a similar
outcome to the Branch Vein Occlusion Study: 62% of patients
gained two or more lines compared with prior treatment.
However, an increase in visual acuity after bevacizumab
treatment is observed after only a very short observation period
and the effect of bevacizumab lasted for 6 months. Further
studies are necessary to evaluate the long-term effect of anti-
VEGF therapy for the treatment of macular oedema secondary
to BRVO.
In summary, we have shown that intravitreal injections of
bevacizumab are an effective treatment option for eyes with
macular oedema due to BRVO. Whether additional laser
photocoagulation would produce additional benefit needs to
be further evaluated. We can recommend this treatment as a
primary approach for eyes with macular oedema secondary to
BRVO.
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